Q: This program is called a Bridge its not a permanent solution
308 Ongoing phase III clinical trials of semaglutide have aimed to further elucidate the efficacy and safety of these drugs in the T1D population (NCT05819138)
Increased Bioavailability & Potency
16 Berenbaum hypothesized that the therapeutic potential of GLP-1 in OA may arise from targeting the crosstalk between macrophages and fibroblasts, which are known to drive inflammation, fibrosis, and downstream cartilage damage
O., Koutsari, C., Blachnio-Zabielska, A
The conversation covers medical therapy, biologic treatments like Tepezza (teprotumumab), surgical options, and the importance of a multidisciplinary approach